Fluoroestradiol (18F)

Phase 2Radiopharmaceutical

AAssistance Publique - Hôpitaux de Paris

Fluoroestradiol (18F) is one of 57 small molecule programs targeting Metastasis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MetastasisActive, not recruiting

Breast CancerActive, not recruiting

MetastasisPhase 2

Active, not recruiting

Breast CancerPreclinical

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tecentriq

Roche

Preclinical

36 2

Tykerb

GSK

Preclinical

80 3

Adriamycin

GGynecologic Oncology Group

Preclinical

87 4

Avastin

BBio-Thera Solutions

Preclinical

153 5

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 6

Prolia

Amgen

Preclinical

14 7

Gemzar

GGynecologic Oncology Group

Preclinical

22 8

Voltaren

Novartis

Preclinical

1 9

Lupron

EEastern Cooperative Oncology Group

Preclinical

5 10

Fluoroestradiol (18F)

AAssistance Publique - Hôpitaux de Paris

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Breast Cancer3 trials

Fluoroestradiol PET Imaging in Predicting Response to Hormone Therapy of Breast Cancer

Completed·AAssistance Publique - Hôpitaux de Paris·N/A·NCT01627704·72 enrolled

Study to Determine the Utility of FES-PET in the Prediction of Response to Fulvestrant in Women With Estrogen Positive Metastatic Breast Cancer

Completed·ZZhimin Shao·N/A·NCT03507088·36 enrolled

Diagnostic Accuracy and Safety Study of FES PET/CT in Assessment of ER Status of Recurrent or Metastatic Breast Cancer

Completed·—·Phase 3·NCT01986569·93 enrolled

Metastasis1 trial

Diagnostic Performance of [18F]FES PET/CT for Axillary LN Metastasis in Invasive Lobular Carcinoma

Completed·—·Phase 2·NCT05960201·23 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Fluoroestradiol (18F). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fluoroestradiol (18F) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fluoroestradiol (18F). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Assistance Publique - Hôpitaux de Paris company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Radiopharmaceutical[2]
Highest Phase: Phase 2[1]
Company: AAssistance Publique - Hôpitaux de Paris

Fluoroestradiol (18F)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Breast Cancer3 trials

Metastasis1 trial

References

Drug Info

Quick Facts

Related News